Introduction {#S1}
============

HSCs give rise to all blood cells, and are characterized by their ability for life-long self-renewal and multilineage differentiation. HSC function is regulated by complex cell-intrinsic^[@R1]^ and -extrinsic pathways^[@R2]^, but the mechanisms that control balanced self-renewal and differentiation are poorly understood. Transcriptional, translational and epigenetic regulators have been shown to critically regulate HSC function^[@R1]^. Whether other molecular mechanisms also regulate HSCs is unclear.

m^6^A is a modified base found in eukaryotic mRNAs^[@R3]^. This modification of adenosine is abundant and functions as an epitranscriptomic regulator of target mRNAs through multiple mechanisms, including stability and translation efficiency^[@R4]^. m^6^A is deposited onto mRNAs by a methyltransferase complex, composed of methyl transferase-like 3 (METTL3), methyl transferase-like 14 (METTL14) and Wilms-tumor associated protein (WTAP) and other accessory proteins^[@R5]^. METTL3 is the essential catalytic component of the complex^[@R6]--[@R9]^. m^6^A has been shown to impact fundamental cellular processes, including DNA damage repair^[@R10]^, meiosis^[@R11]^, and circadian clock^[@R12]^. Transcriptome-wide mapping of m^6^A modification has revealed cell type-specific methylation targets, suggesting that m^6^A regulates cell type-specific processes^[@R13]^. Interestingly, m^6^A has been shown to impact stem and progenitor cell fate. Disruption of the m^6^A pathway blocks the decay of naïve embryonic stem cell program^[@R6],[@R14]^. m^6^A also plays a critical role in embryonic neurogenesis by regulating fatal neural stem and progenitor cells^[@R15],[@R16]^. The role of m^6^A in the haematopoietic system is emerging. Using zebrafish as a model, it has been shown that m^6^A is required for endothelial to haematopoietic transition and the emergence of haematopoietic stem and progenitor cells^[@R17]^. shRNA knockdown of *Mettl3* or *Mettl14* in human haematopoietic stem and progenitor cells leads to myeloid differentiation *in vitro*^[@R18],[@R19]^. These studies show that m^6^A plays critical roles for HSC emergence and *in vitro* function, but its role in mammalian adult HSCs and haematopoiesis *in vivo* remained unclear.

Results {#S2}
=======

Deletion of Mettl3 disrupts haematopoiesis and leads to accumulation of HSCs {#S3}
----------------------------------------------------------------------------

We performed quantitative real-time PCR (qPCR) analysis to assess the expression of *Mettl3* in the haematopoietic system. *Mettl3* transcripts were expressed at approximately 4.5-fold higher levels in CD150^+^CD48^−^Lin^−^Sca1^+^cKit^+^ HSCs compared with whole bone marrow cells ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}), suggesting that METTL3-mediated m^6^A may regulate the function of HSCs.

To test whether m^6^A regulates HSCs and haematopoiesis *in vivo*, we generated and validated a floxed allele of *Mettl3* ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}), and crossed it with *Mx1-cre*^[@R20]^ to generate *Mx1-cre; Mettl3*^*fl/fl*^ mice. We conditionally deleted *Mettl3* from the adult haematopoietic cells by intraperitoneally injecting polyinosinic-polycytidylic acid (pIpC) into 6--8 week old *Mx1-cre; Mettl3*^*fl/fl*^ mice ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). Efficient deletion in HSCs was achieved by 10 days after the last pIpC injection ([Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"} and [d](#SD1){ref-type="supplementary-material"}). Ten to 14 days (short term) after the last pIpC injection, complete blood count analyses revealed a significant decrease in platelet count in *Mx1-cre; Mettl3*^*fl/fl*^ mice compared with pIpC-treated controls ([Figs. 1a](#F1){ref-type="fig"}, [b](#F1){ref-type="fig"} and [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Recent work in the field has proposed that platelets can be directly generated from HSCs^[@R21],[@R22]^. The platelet phenotype raises the possibility that m^6^A may regulate HSCs. The same phenotype persisted 2--3 months after the last pIpC injection ([Figs. 1a](#F1){ref-type="fig"}, [b](#F1){ref-type="fig"} and [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). By 4 months, white blood cell counts were also significantly reduced, with an altered white blood cell distribution ([Figs. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). These data suggest that m^6^ A is required for haematopoiesis.

Deletion of *Mettl3* led to a significant reduction in bone marrow cellularity ([Fig. 1c](#F1){ref-type="fig"}), but not spleen cellularity 10--14 days after the last pIpC injection ([Figs. 1d](#F1){ref-type="fig"} and [e](#F1){ref-type="fig"}). However, by 2--4 months after the last pIpC injection, in addition to a significant bone marrow cellularity reduction, the spleen size and cellularity were significantly increased with a distortion of cell type distribution ([Figs. 1c](#F1){ref-type="fig"}--[e](#F1){ref-type="fig"} and [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). The spleens contained more HSCs in *Mx1-cre; Mettl3*^*fl/fl*^ mice compared with controls ([Fig. 1f](#F1){ref-type="fig"}). These data are suggestive of extramedullary haematopoiesis after loss of m^6^A.

In the bone marrow, Lin^−^Sca1^+^cKit^+^ (LSK) haematopoietic progenitors ([Fig. 1g](#F1){ref-type="fig"}) and HSCs ([Fig. 1h](#F1){ref-type="fig"} and [Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"} and [e](#SD1){ref-type="supplementary-material"}) were significantly increased at all time points examined. The HSC pool uniquely expanded over time from 10--14 days to 4 months after the last pIpC injection: progressing from a 3-fold to a 17-fold increase in HSC frequency ([Figs. 1h](#F1){ref-type="fig"}, [Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"} and [e](#SD1){ref-type="supplementary-material"}). In contrast, CD150^−^CD48^−^LSK MPP frequency was not significantly increased while CD150^−^CD48^+^LSK progenitor frequency was only modestly increased ([Fig. 1i](#F1){ref-type="fig"} and [Supplementary Fig. 2f](#SD1){ref-type="supplementary-material"}). CD150^+^CD48^+^LSK megakaryocyte-skewed multipotent progenitor frequency was significantly increased ([Supplementary Fig. 2f](#SD1){ref-type="supplementary-material"}), suggesting that there is also an effect on the megakaryocyte lineage. Thus, at the top of the haematopoietic hierarchy, loss of m^6^A preferentially leads to HSC accumulation.

We also examined other haematopoietic progenitors in the bone marrow. These included Lin^−^Sca1^low^cKit^low^Flt3^+^IL7Rα^+^ common lymphoid progenitors (CLPs), CD34^+^FcγR^−^Lineage^−^Sca1^−^cKit^+^ common myeloid progenitors (CMPs), CD34^+^FcγR^+^Lineage^−^Sca1^−^cKit^+^ granulocyte/macrophage progenitors (GMPs), and CD34^−^FcγR^−^Lineage^−^Sca1^−^cKit^+^ megakaryocytic/erythroid progenitors (MEPs). The frequencies of these haematopoietic progenitors were unchanged in *Mx1-cre; Mettl3*^*fl/fl*^ mice compared with controls until 4 months after the last pIpC treatment, when there was a modest decrease in GMP and a modest increase in MEP frequencies ([Supplementary Fig. 2g](#SD1){ref-type="supplementary-material"}). There was a significant increase in Lin^−^Sca1^−^cKit^+^CD150^+^CD41^+^ megakaryocyte progenitors and CD41^+^ megakaryocytic cells in the bone marrow ([Fig. 1j](#F1){ref-type="fig"} and [k](#F1){ref-type="fig"}), suggesting that the reduction in platelet counts ([Fig. 1b](#F1){ref-type="fig"}) is due to a differentiation defect in the megakaryocyte lineage. These data suggest that loss of *Mettl3* preferentially impacts HSCs, with effects on the megakaryocyte lineage.

Deletion of Mettl3 preferentially blocks HSC differentiation {#S4}
------------------------------------------------------------

HSCs from pIpC-injected *Mx1-cre; Mettl3*^*fl/fl*^ mice did not incorporate more BrdU ([Fig. 2a](#F2){ref-type="fig"}), but underwent slightly more cell death ([Fig. 2b](#F2){ref-type="fig"}), suggesting that the accumulation of HSCs may be the result of blocked differentiation rather than enhanced self-renewal. The *Mettl3*-deficient HSCs did not have elevated levels of reactive oxygen species (ROS) or γH2Ax staining ([Supplementary Fig. 2h](#SD1){ref-type="supplementary-material"} and [i](#SD1){ref-type="supplementary-material"}). Consistent with an HSC differentiation defect, pIpC-injected *Mx1-cre; Mettl3*^*fl/fl*^ mice had worse survival compared to controls when challenged with a myeloablative agent, 5-fluorouracil (5FU) ([Fig. 2c](#F2){ref-type="fig"}).

To directly assess the differentiation potential of *Mettl3*-deficient HSCs, we performed methylcellulose assays. Single HSCs from pIpC-treated *Mx1-cre; Mettl3*^*fl/fl*^ or control mice were directly sorted into methylcellulose, which supports myelo-erythroid differentiation *in vitro*^[@R23],[@R24]^. Significantly fewer *Mettl3*-deficient HSCs formed colonies compared with control HSCs, particularly multipotent granulocyte, erythrocyte, monocyte and megakaryocyte (GEMM) colonies ([Fig. 2d](#F2){ref-type="fig"}). The vast majority of the colonies formed by *Mettl3*-deficient HSCs were significantly smaller compared with those formed by control HSCs ([Fig. 2e](#F2){ref-type="fig"} and [Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Flow cytometric analysis on cells from these colonies showed that *Mettl3*-deficient HSCs failed to differentiate while control HSCs readily differentiated into Gr1^+^ and Mac1^+^ myeloid cells ([Figs. 2f](#F2){ref-type="fig"} and [h](#F2){ref-type="fig"}). A few colonies were formed at normal sizes by *Mettl3*-deficient HSCs and genotyping revealed that these colonies had escaped complete *Mettl3* deletion ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"} and [c](#SD1){ref-type="supplementary-material"}). *Mettl3*-deficient HSCs in the spleens also failed to differentiate ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}).

In contrast, when *Mettl3*-deficient whole bone marrow cells were plated into methylcellulose, colonies formed at similar numbers, size and types compared with controls ([Fig. 2g](#F2){ref-type="fig"}). We further plated sorted *Mettl3*-deficient restricted progenitors (LSK, CD150^−^CD48^+^LSK and CD150^+^CD48^+^LSK), into methylcellulose. They formed normal numbers of colonies, similar in size and type compared with controls ([Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}). Flow cytometry analysis confirmed that these colonies contained normal numbers of differentiated cells ([Fig. 2h](#F2){ref-type="fig"} and [Supplementary Fig. 3f](#SD1){ref-type="supplementary-material"}). Taken together, these data suggest that loss of *Mettl3* preferentially leads to a differentiation block in HSCs but not in restricted progenitors *in vitro*.

Deletion of *Mettl3* leads to cell-intrinsic HSC reconstitution and differentiation defects *in vivo* {#S5}
-----------------------------------------------------------------------------------------------------

To test whether loss of *Mettl3* leads to HSC defects *in vivo*, we performed competitive reconstitution assays by transplanting 500,000 bone marrow cells from *Mx1-cre; Mettl3*^*fl/fl*^ or control mice 10 days after the last pIpC injection along with 500,000 wild-type competing bone marrow cells into lethally irradiated recipient mice. *Mettl3*-deficient bone marrow cells contributed significantly lower levels of overall, myeloid, B and T lineage cells in the peripheral blood and a trend towards lower levels of HSCs in the bone marrow compared with controls ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). Genotyping analysis on sorted residual donor-derived peripheral blood cells demonstrated that these residual cells escaped complete *Mettl3* deletion ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). To specifically test whether HSCs were functionally defective, we sorted and transplanted *Mettl3*-deficient and control HSCs along with wild-type competing bone marrow cells into lethally irradiated mice. While control HSCs readily reconstituted the recipient mice in all major haematopoietic lineages, *Mettl3*-deficient HSCs failed to give any discernable reconstitution ([Fig. 3b](#F3){ref-type="fig"} and [Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). These data suggest that *Mettl3*-deficient HSCs are defective in reconstituting recipient mice.

To determine whether *Mettl3* is required cell-intrinsically for HSC function, we transplanted *Mx1-cre; Mettl3*^*fl/fl*^ or control bone marrow cells, without pIpC treatment, along with wild-type competitor bone marrow cells into irradiated recipient mice. We waited at least 8 weeks after transplantation for stable bone marrow chimerism to be established. *Mettl3* was then deleted by pIpC injection and donor-derived peripheral blood cells were monitored over time. Overall reconstitution by *Mettl3-*deficient bone marrow cells was significantly lower than controls ([Fig. 3c](#F3){ref-type="fig"}). The reconstitution defects were mainly in the myeloid and B lineages, but not in the T cell lineages ([Fig. 3c](#F3){ref-type="fig"}), consistent with the slow turnover kinetics of T cells in adults *in vivo*. After 16 weeks, the recipient mice were sacrificed and analyzed for the frequencies of donor-derived bone marrow HSCs and haematopoietic progenitors. *Mettl3*-deficient HSCs were present at similar levels compared with control HSCs ([Fig. 3d](#F3){ref-type="fig"}), suggesting that HSC self-renewal is largely normal. However, these HSCs generated gradually less mature haematopoietic cells along the differentiation hierarchy ([Fig. 3d](#F3){ref-type="fig"}). Consistent with the depletion of donor-derived myeloid cells in the peripheral blood ([Fig. 3c](#F3){ref-type="fig"}), very little CMPs, GMPs and MEPs were derived from *Mettl3*-deficient HSCs ([Fig. 3d](#F3){ref-type="fig"}). Genotyping on sorted donor-derived cells in recipient mice showed that these residual cells escaped complete *Mettl3* deletion ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). These data suggest that *Mettl3* is required for HSC differentiation *in vivo*.

We also conditionally deleted *Mettl3* from haematopoietic cells using *Rosa26-creER*^[@R25]^. We noncompetitively transplanted bone marrow cells from *Rosa26-creER; Mettl3*^*fl/fl*^ mice into irradiated recipient mice and then deleted *Mettl3* by administering tamoxifen. Deletion of *Mettl3* led to a significantly higher frequency of HSCs in the recipient mice ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}), recapitulating the *Mx1-cre; Mettl3*^*fl/fl*^ model ([Fig. 1h](#F1){ref-type="fig"}). We also competitively transplanted *Rosa26-creER; Mettl3*^*fl/fl*^ bone marrow cells together with recipient-type bone marrow cells and waited at least 8 weeks after transplantation for stable bone marrow chimerism before administering tamoxifen. Tamoxifen-induced deletion of *Mettl3* also led to a significant reduction in reconstitution activity ([Supplementary Fig. 4f](#SD1){ref-type="supplementary-material"}), similar to *Mx1-cre; Mettl3*^*fl/fl*^ mice ([Fig. 3c](#F3){ref-type="fig"}).

*Mettl3* is not required for myelopoiesis {#S6}
-----------------------------------------

To directly test whether the observed predominant myeloid lineage reconstitution defect ([Fig. 3c](#F3){ref-type="fig"}) was a consequence of loss of *Mettl3* in myeloid cells, we conditionally deleted *Mettl3* from myeloid cells by generating *Lysm-cre; Mettl3*^*fl/fl*^ mice. Consistent with previous reports^[@R26]^, *Lysm-cre* efficiently recombined in bone marrow myeloid cells ([Supplementary Fig. 4g](#SD1){ref-type="supplementary-material"}). Six-8 week old *Lysm-cre; Mettl3*^*fl/fl*^ mice had normal peripheral blood counts ([Figs. 4a](#F4){ref-type="fig"} and [b](#F4){ref-type="fig"}, and [Supplementary Fig. 4h](#SD1){ref-type="supplementary-material"}), normal bone marrow and spleen cellularity ([Fig. 4c](#F4){ref-type="fig"} and [Supplementary Fig. 4i](#SD1){ref-type="supplementary-material"}), and normal frequencies of myeloid cells in the bone marrow and spleens ([Fig. 4d](#F4){ref-type="fig"}).

*Mettl3*-deficient bone marrow myeloid cells from *Lysm-cre; Mettl3*^*fl/fl*^ mice formed macrophages with normal morphology ([Supplementary Fig. 4j](#SD1){ref-type="supplementary-material"}). When challenged with lipopolysaccharide (LPS), these macrophages showed normal up-regulation of inflammatory cytokines, *Tnfa*, *Il1b* and *Il6* ([Fig. 4e](#F4){ref-type="fig"}). *Mettl3*-deficient bone marrow-derived macrophages also displayed robust engulfing activity, similar to controls ([Fig. 4f](#F4){ref-type="fig"}). These data suggest that *Mettl3* is not required for the maintenance or function of mature myeloid cells and the observed reconstitution deficiencies ([Fig. 3c](#F3){ref-type="fig"}) are a consequence of HSC differentiation defects. Furthermore, these data provide conclusive evidence that there is a stage-specific dependence on *Mettl3* and m^6^A during haematopoietic differentiation *in vivo*.

Identification of m^6^A targets in HSCs {#S7}
---------------------------------------

To identify direct m^6^A targets in rare HSCs, we developed an m^6^A-tagged mRNA immunoprecipitation sequencing (meRIP-seq) method to analyze the m^6^A methylome of 2,000 freshly sorted wild-type HSCs from 6--8 week old mice ([Supplementary Figs. 5a](#SD1){ref-type="supplementary-material"} and [b](#SD1){ref-type="supplementary-material"}). 2,073 transcripts (FDR\<0.05 and fold\>2) were significantly enriched in the m^6^A antibody-bound fraction compared to the non-bound fraction and were defined as high-confidence m^6^A targets ([Figs. 5a](#F5){ref-type="fig"} and [b](#F5){ref-type="fig"}, and [Supplementary Table 1](#SD3){ref-type="supplementary-material"}). This represented only \~9% of the genes expressed in the input mRNA fraction, suggesting that m^6^A preferentially marks a subset of genes in HSCs. We also performed meRIP-seq on *Mettl3*-deficient HSCs from *Mx1-cre; Mettl3*^*fl/fl*^ mice 10 days after pIpC administration. The enrichment of 995 transcripts (\~48% of the high-confidence m^6^A targets) was significantly reduced (p\<0.05) in *Mettl3*-deficient HSCs, suggesting that the m^6^A modification of these targets depended acutely on METTL3 ([Supplementary Figs. 5c](#SD1){ref-type="supplementary-material"} and [d](#SD1){ref-type="supplementary-material"}). The lack of complete elimination of m^6^A may be due to residue METTL3 protein, slow turnover of some target mRNAs or antibody detection of cap region m^6^Am, which unlike m^6^A, is known not to be regulated by *Mettl3* but is also detected by the anti-m^6^A antibodies used^[@R5]^.

Gene ontology (GO) analysis of m^6^A-tagged mRNAs demonstrated enrichment of genes related to nucleic acid metabolism, cell cycle regulation, transcription, RNA binding, and cellular stress responses, immune system development and haematopoiesis ([Supplementary Fig. 5e](#SD1){ref-type="supplementary-material"}). Supporting feed-forward regulation, several genes encoding components of the m^6^A pathway, including WTAP and m^6^A-reader proteins^[@R5]^, were also targets of m^6^A ([Supplementary Fig. 5f](#SD1){ref-type="supplementary-material"}). Consistent with the differentiation defects observed in *Mettl3*-deficient HSCs ([Figs. 1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"}), we observed significant enrichment of genes associated with haematopoietic differentiation ([Supplementary Fig. 5e](#SD1){ref-type="supplementary-material"}). These data suggest that m^6^A regulates HSC differentiation by directly targeting haematopoietic differentiation pathways. Several known HSC regulators were identified as major targets of m^6^A, including *Myc*, *Junb*, and *Tet2* ([Fig. 5b](#F5){ref-type="fig"}). More importantly, the enrichment of these genes in the m^6^A-bound fraction was significantly decreased when *Mettl3* was deleted from HSCs, suggesting the m^6^A modification of these genes is dependent on METTL3 ([Fig. 5c](#F5){ref-type="fig"} and [Supplementary Figs. 5c](#SD1){ref-type="supplementary-material"} and [d](#SD1){ref-type="supplementary-material"}).

Deletion of *Mettl3* leads to a loss of HSC identity without drastic alterations of the transcriptome {#S8}
-----------------------------------------------------------------------------------------------------

To further understand the molecular mechanisms underpinning the functional defects of *Mettl3*-deficient HSCs, we performed RNA-seq analysis on *Mettl3*-deficient HSCs using Smart-seq2^[@R27]^. 830 genes showed significant expression differences (p\<0.05) ([Supplementary Table 2](#SD4){ref-type="supplementary-material"}). After stringent analysis with multiple comparisons correction, only 7 genes showed significant expression differences (FDR\<0.05) between *Mettl3*-deficient and control HSCs ([Supplementary Fig. 6a](#F5){ref-type="fig"} and [Supplementary Table 2](#SD4){ref-type="supplementary-material"}). As expected, *Mettl3* was one of the most significantly down-regulated genes in *Mettl3*-deficient HSCs ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}). Gene set enrichment analysis (GSEA)^[@R28]^ showed that *Mettl3* deficiency predominantly led to a loss of expression of HSC identity-associated genes defined by previous publications^[@R29]--[@R31]^ ([Fig. 5d](#F5){ref-type="fig"} and [Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). These data suggest that METTL3-mediated m^6^A modestly altered HSC identity without profoundly impacting global mRNA levels.

m^6^A has been shown to negatively regulate target mRNA stability^[@R4]^. We thus assessed whether m^6^A targets were up-regulated in *Mettl3*-deficient HSCs. 95 out of 384 up-regulated genes in *Mettl3*-defieient HSCs (p\<0.05 and fold\>1.2) were m^6^A targets ([Supplementary Table 2](#SD4){ref-type="supplementary-material"} and [Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). But none of the 7 high-confidence differentially expressed genes (FDR\<0.05) ([Supplementary Table 1](#SD3){ref-type="supplementary-material"} and [Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}) were high-confidence m^6^A targets. Compared to non-m^6^A targets, transcripts of m^6^A targets had slightly increased abundance in *Mettl3*-deficient HSCs ([Fig. 5e](#F5){ref-type="fig"}). Taken together, these data suggest that although m^6^A may directly control the transcript levels of some genes, it predominantly regulates target mRNAs post-transcriptionally in HSCs.

*Myc* is a direct target of m^6^A in HSCs {#S9}
-----------------------------------------

It has been shown that the MYC protein level is very low in HSCs, and is up-regulated upon differentiation through post-transcriptional mechanisms^[@R32],[@R33]^. Furthermore, deletion of *Myc* blocks HSC differentiation while accumulated higher levels of MYC protein promotes HSC differentiation^[@R32],[@R34]^. Prompted by the observations that *Myc* is a major determinant of HSC differentiation and the phenotypic similarity between *Myc* and *Mettl3* conditional knockout mice (accumulation of HSCs and blockage of differentiation), we investigated whether *Myc* is a direct target of m^6^A in HSCs. Our meRIP-seq analyses revealed that *Myc* was one of the top candidates highly enriched in m^6^A antibody-bound fraction compared with non-bound fraction (\~30 fold enrichment; FDR=3.96×10^−15^) ([Figs. 5b](#F5){ref-type="fig"} and [c](#F5){ref-type="fig"}), in a *Mettl3*-dependent manner ([Fig. 5c](#F5){ref-type="fig"} and [Supplementary Figs. 5c](#SD1){ref-type="supplementary-material"} and [d](#SD1){ref-type="supplementary-material"}). We confirmed these meRIP-seq data using qPCR on independent samples ([Fig. 6a](#F6){ref-type="fig"}). Interestingly, *Myc* transcript levels were not significantly changed in *Mettl3*-deficient HSCs compared with controls ([Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"}). Using several previously published *Myc* target gene sets^[@R35],[@R36]^, GSEA revealed a significant decrease in *Myc* target gene signatures in *Mettl3*-deficient HSCs ([Fig. 6b](#F6){ref-type="fig"} and [Supplementary Fig. 6e](#SD1){ref-type="supplementary-material"}), suggesting that m^6^A may primarily regulate *Myc* mRNA translation.

The *Myc* protein level can be directly measured by a knockin *Myc-*GFP translational reporter *in vivo*^[@R37]^. To assess the impact of *Mettl3* deletion on the level of *Myc* protein in HSCs, we generated *Mx1-cre; Mettl3*^*fl/fl*^*; Myc-GFP* mice. Consistent with prior publications^[@R32],[@R33]^, HSCs express low levels of MYC-GFP compared to haematopoietic progenitors at steady state ([Fig. 6c](#F6){ref-type="fig"}). Deletion of *Mettl3* led to a modest significant reduction of MYC-GFP in HSCs ([Fig. 6c](#F6){ref-type="fig"}). Remarkably, upon activation to differentiate, *Mettl3*-deficient HSCs failed to up-regulate MYC-GFP while control HSCs could readily do so ([Fig. 6d](#F6){ref-type="fig"}). *Mettl3* deletion did not lead to changes in HSC *Myc* transcript levels under the activation condition ([Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"}). Given that m^6^A primarily regulates target mRNA stability and translation^[@R5],[@R38]^, these data suggest that m^6^A is required for *Myc* mRNA translation in HSCs, particularly upon differentiation.

We tested whether forced expression of *Myc* can rescue the HSC differentiation defects caused by *Mettl3* deletion. We transduced *Mettl3*-defiecent HSCs with *Myc*-expressing or control retrovirus ([Fig. 6e](#F6){ref-type="fig"} and [Supplementary Fig. 6f](#SD1){ref-type="supplementary-material"}) and assessed their differentiation potential *in vitro*. Forced expression of *Myc* significantly rescued the differentiation defect of *Mettl3*-deficient HSCs compared with controls ([Fig. 6e](#F6){ref-type="fig"}). These data indicate that *Myc* is one of the major functional targets of m^6^A in HSCs.

Discussion {#S10}
==========

We demonstrate that m^6^A is preferentially required for adult HSC differentiation *in vivo* and *in vitro*, but not mature myeloid cell maintenance or function. These results demonstrate that m^6^A is not a general cellular house-keeping mechanism, but rather a modification with specific roles in HSCs. Our results are in contrast to reports that show m^6^A inhibits differentiation of CD34^+^ human haematopoietic progenitor cells *in vitro*^[@R18],[@R19]^. Since those experiments were performed using shRNAs on cells of mixed populations of HSCs and progenitors *in vitro*, it is not clear what the effects on human HSCs are *in vivo*. Of note, we observed differences between HSCs and progenitors in their response to *Mettl3* deletion ([Fig. 2](#F2){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), suggesting that the roles of m^6^A in HSCs and progenitors need to be assessed independently. Consistent with our data, Yao *et al* recently showed that conditional deletion of *Mettl3* led to accumulation of HSCs in the bone marrow while our paper was under review^[@R39]^.

In contrast to its role in enabling HSC differentiation, m^6^A inhibits differentiation in AML leukemic cells^[@R18],[@R19],[@R40]^. This surprising difference may reflect distinct mechanisms of action for m^6^A in leukemic cells and HSCs, and suggests that it may be possible to develop m^6^A-targeted therapies against leukemia cells without damaging HSC function. More work is needed to elucidate the differences in the role of m^6^A between leukemic cells and HSCs.

We found that HSC self-renewal and quiescence is largely intact after *Mettl3* deletion ([Figs. 2a](#F2){ref-type="fig"} and [3d](#F3){ref-type="fig"}). Thus, it appears that m^6^A specifically regulates HSC differentiation. m^6^A-mediated epitranscriptional regulation in HSCs may provide a fast and flexible mechanism to control mature blood cell output, allowing the organism to adapt to ever-changing physiological demands. *Mettl3*-deficient HSCs failed to establish bone marrow chimera in transplantation ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"} and [c](#SD1){ref-type="supplementary-material"}), suggesting that m^6^A may regulate HSC homing and/or engraftment, which will be interesting to further investigate in the future.

Methods {#S11}
=======

Mice {#S12}
----

*Mx1-cre*^[@R20]^, *Lysm-cre*^[@R26]^*, Myc-GFP*^[@R37]^ mice were obtained from the Jackson Laboratory and maintained on C57BL/B6 background. *Rosa26-creER* mice^[@R25]^ were generated and provided by Dr. T. Ludwig at Columbia University. *Mettl3*^*fl*^ mice were generated by electroporation of a targeting vector (obtained from the Knockout Mouse Project Repository, KOMP) into V6.5 embryonic stem (ES) cells. Correctly targeted ES cell clone, validated by PCR and southern blot analysis, was identified and injected into BDF1 blastocysts and chimeric mice were generated. Chimeric mice were bred with C57BL/6 mice to obtain germline transmission. The resulting mice were crossed with Flpe mice^[@R41]^ to remove the Neo cassette. These mice were backcrossed at least 6 times onto C57BL/6 background before analysis. To induce Cre expression in *Mx1-cre; Mettl3*^*fl/fl*^ mice, 6--8wk old animals were intraperitoneally injected with 10ug polyinosinic-polycytidylic acid (pIpC, GE or InvivoGen) in PBS every other day for 5 injections. Mice were analyzed either 10--14 days, 2--3 months, or 4 months after the final injection, as indicated in each experiment. To induce Cre expression in *Rosa26-CreERT2; Mettl3*^*fl/fl*^ mice, recipients were given 1ug tamoxifen in 50uL corn oil by gavage every other day for 5 doses. All mice were housed in specific pathogen-free, Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)-approved facilities at the Columbia University Medical Center. All protocols were approved by the Institute Animal Care and Use Committee of Columbia University. The study is compliant with all relevant ethical regulations regarding animal research.

Genotyping PCR Primers {#S13}
----------------------

The following primers were used for genotyping:

*Mettl3*^*fl*^ allele: OLD810: GTTGATGAAATTATCAGTACAATGGTTCTGA; OLD811: GTAAAGAACAACTCTGGTTATCGTCATCG.

*Mettl3* deletion allele: OLD812: GGATGATTTCTTCTACCATTACCTCTACCC;

OLD813: CAGAAAGCCCATCCTCAGCGTG.

5FU administration {#S14}
------------------

For 5-fluorouracil (5-FU; Sigma-Aldrich) treatment, *Mx1-cre; Mettl3*^*fl/fl*^ and littermate control mice were treated with pIpC as previously described. 10 days after the last pIpC injection, mice were injected intraperitoneally with 150 mg/kg 5-FU weekly until death or experimental conclusion.

Complete Blood Counts {#S15}
---------------------

Peripheral blood was collected by tail vein or cardiac puncture into EDTA-coated capillary tubes. Blood samples were analyzed by Genesis (Oxford Science Inc).

Flow cytometry {#S16}
--------------

Bone marrow cells were isolated by flushing the long bones or by crushing the long bones, pelvis, and vertebrae with mortar and pestle in Ca^2+^ free and Mg^2+^ free HBSS with 2% heat-inactivated bovine serum. Splenic cells were obtained by crushing the spleens between two glass slides. The splenic and bone marrow cells were passed through a 25G needle several times and filtered through 70μm nylon mesh. The following antibodies were used to perform HSC staining: lineage markers (anti-CD2 (RM2--5), anti-CD3 (17A2), anti-CD5 (53--7.3), anti-CD8a (53--6.7), anti-B220 (6B2), anti-Gr-1 (8C5), anti-Ter119), anti-Sca-1 (E13--161.7), anti-c-kit (2B8), anti-CD48 (HM48--1), anti-CD150 (TC15--12F12.2). Additionally, the following antibodies were used to perform haematopoietic progenitor staining as previously described^[@R24]^: lineage markers (anti-CD2 (RM2--5), anti-CD3 (17A2), anti-CD5 (53--7.3), anti-CD8a (53--6.7), anti-B220 (6B2), anti-Gr-1 (8C5), anti-Ter119), anti-Sca-1 (E13--161.7), anti-c-kit (2B8), anti-CD34 (RAM34), anti-FLT3 (A2F10), anti-CD16/32 (93), anti-IL7Rα (A7R34).

Cell cycle, DNA damage, cell death, reactive oxygen species analysis. {#S17}
---------------------------------------------------------------------

For BrdU incorporation analysis, mice intraperitoneally injected with 0.1mg/kg BrdU and maintained on 0.5mg/ml BrdU water for 5 days before the analysis. The frequency of BrdU^+^ cells was determined by flow cytometry using an APC BrdU Flow Kit (BD Biosciences) per manufacturer's instructions. To measure γH2AX levels, cells were stained for SLAM markers, fixed and permeabilized (BD Biosciences BrdU Flow Kit) and stained with anti-γH2AX (Biolegend, clone 2F3), followed by flow cytometry. Annexin V staining was performed using Annexin V Apoptosis Detection Kit APC (eBioscience) per manufacturer's instructions. ROS levels were measured by DCFDA staining (29--79-dichlorofluorescein diacetate, ThermoFisher Scientific). After antibody staining, cells were incubated with 10uM DCFDA for 15 minutes at 37°C, followed by flow-cytometry.

Long-term competitive reconstitution assay {#S18}
------------------------------------------

Adult recipient mice were lethally irradiated by a Cesium 137 Irradiator (JL Shepherd and Associates) at 300 rad/min with two doses of 540 rad (total 1080 rad) delivered at least two hours apart. Cells were transplanted by retro-orbital venous sinus injection of anesthetized mice. Mice were transplanted with either 5 × 10^5^ donor and 5 × 10^5^ competitor bone marrow cells or 50 sorted donor HSCs and 3 × 10^5^ competitor bone marrow cells, as indicated. Donor mice were either untreated or sacrificed10 days after pIpC treatment, as indicated. Recipient mice were temporarily maintained on antibiotic water (Baytril 0.17g/L) for 14 days after transplantation. Peripheral blood from recipient mice was analyzed by flow cytometry at indicated timepoints for at least 16 weeks after transplantation to assess the level of donor-derived blood lineages (donor chimerism), including myeloid, B, and T cells. For post-transplantation Cre-induction experiments, recipients' peripheral blood was analyzed over at least two time points at least 6--8 weeks after transplantation to ensure stable engraftment before treatment with pIpC (10ug per mouse per dose for 5 doses) or tamoxifen (1ug per mouse per dose for 5 doses). Blood was subjected to ammonium chloride potassium red cell lysis before antibody staining. Antibodies including anti-CD45.2 (104), anti-CD45.1 (A20), anti-CD3 (17A2), anti-B220 (6B2), anti-Gr1 (8C5), and anti-Mac1 (M1/70) were used to stain cells.

Colony-forming unit assay {#S19}
-------------------------

10,000 bone marrow cells, 100,000 spleen cells, 200 LSK cells, single MPP, single HSCs or other haematopoietic progenitors were plated in methylcellulose culture medium (3434, STEMCELL Technologies) and incubated at 37°C. Colonies were counted 9--12 days after plating on an Olympus CKX41 microscope (Olympus) and scored as derived from erythroid progenitor cells (BFU-E and CFU-E), granulocyte-macrophage progenitor cells (CFU-GM, CFU-G and CFU-M), megakaryocyte progenitor cells (CFU-MK) and multipotent granulocyte, erythroid, macrophage and megakaryocyte progenitor cells (CFU-GEMM).

Viral transduction and colony-forming assay {#S20}
-------------------------------------------

Retroviruses were produced by transfecting 293T cells with pMIG-Myc (Addgene plasmid \#18119) or pMIG vectors along with pCL-Eco and collecting media after 48--72hrs. Virus titers were determined by transduction of NIH-3T3 fibroblasts with serial dilutions of viral media. 200 HSCs were sorted from *Mx1-cre; Mettl3*^*fl/fl*^ mice 10 days after pIpC treatment and plated into DMEM with 15% heat-inactivated fetal bovine serum, 100ng/ml SCF, 10ng/ml IL-3, 10ng/ml IL-6 and 50μM b-mercaptoethanol. Cells were transduced with \>120 MOI retrovirus particles in the presence of 8ug/mL polybrene and spun at 1400g for 1.5hrs at 20°C. Cells were then collected and plated in 1.5mL of methylcellulose culture medium and incubated at 37°C for 9--12 days. Colonies were collected in bulk and resuspended in Ca2^+^- and Mg2^+^-free HBSS with 2% heat-inactivated bovine serum before staining with antibodies. Cells were then analyzed by flow cytometry.

Macrophage Culture and phagocytosis assay {#S21}
-----------------------------------------

One million whole bone marrow cells were plated in 12-well plates and cultured at 37°C in Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher) supplemented with 10% Fetal Bovine Serum (LifeTech) and 30% L929 supernatant. After 6 days, non-adherent cells were removed and macrophages were re-plated in fresh medium. Stimulation and phagocytosis assays were carried out on the 7th day.

For stimulation assays, 1ug/mL lipopolysaccharides (LPS; Sigma) were added to cells for 3 hours. Stimulated and unstimulated control cells were harvested into Trizol (Invitrogen) and RNA was isolated according to manufacturer's instructions. Samples were reverse transcribed and subject to qPCR, as previously described.

For phagocytosis assays, cells were incubated for 1 hours at 37°C or 4°C at a multiplicity of infection (MOI) of 1∶50 with Fluoresbrite® carboxylate microspheres (Polyscience), washed in PBS with 1% FBS. Non-adherent cells and excess microspheres were removed by washing with DMEM before macrophages were collected and analyzed by flow cytometry.

qRT-PCR {#S22}
-------

Cells were sorted directly into Trizol. Total RNA was extracted according to manufacturer's instructions. Total RNA was subjected to reverse transcription using SuperScript III (Invitrogen). Quantitative real-time PCR was run using SYBR green on a CFX Connect (Biorad) system. β-actin was used to normalize the RNA content of samples. Primer sequences: *β-actin*: GCTCTTTTCCAGCCTTCCTT; CTTCTGCATCCTGTCAGCAA. *Mettl3*: AAGGAGCCGGCTAAGAAGTC; TCACTGGCTTTCATGCACTC. *Myc*: TCTCCCCAAGGGAAGACGAT; TTGCTCTTCTTCAGAGTCGCT *Tnfa*: GGAACTGGCAGAAGAGGCACTC; GCAGGAATGAGAAGAGGCTGAGAC. *Il6*: CCTCTGGTCTTCTGGAGTACC; ACTCCTTCTGTGACTCCAGC. *Il1b*: GCACTACAGGCTCCGAGATGAAC; TTGTCGTTGCTTGGTTCTCCTTGT.

MeRIP-qPCR {#S23}
----------

poly(A)+RNA was isolated from whole bone marrow cells or sorted HSCs using Dynabeads Oligo-(dT)25 magnetic beads (ThermoFisher Scientific) according to manufacturer's instructions. 1.25 μg of anti-m^6^A antibody (Synaptic Systems) was pre-bound to Protein A/G magnetic beads (Millipore) in IP buffer (20-mM Tris pH 7.5, 140-mM NaCl, 1% NP-40, 2-mM EDTA) for 1 h. Sample RNA was incubated with antibody-bound Protein A/G beads for 2 hours at 4 °C. Samples were washed twice in low-salt-wash buffer (10-mM Tris pH 7.5, 5 mM EDTA), twice with high-salt-wash buffer (20-mM Tris pH 7.5, 1-M NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1-mM EDTA) and twice with RIPA buffer (20-mM Tris pH 7.5, 150-mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1-mM EDTA). All wash solutions for each sample were collected as the "unbound" fraction. RNA was eluted from the beads by incubating with 50μl 20mM N6-methyladenosine 5-monophosphate sodium salt (Sigma-Aldrich) for 1hr at 4 °C. Following ethanol precipitation, input, unbound, and m^6^A-bound fraction RNA was reverse-transcribed using Superscript III (Invitrogen) with random hexamers. Enrichment of m^6^A-containing transcripts was determined by quantitative PCR relative to *Rplp0* expression. The primer sequences for *Rplp0*: GATGGGCAACTGTACCTGACTG and CTGGGCTCCTCTTGGAATG.

RNA-seq and meRIP-seq {#S24}
---------------------

For RNA-seq, libraries were prepared according to the Smart-seq2 protocol as described^[@R27]^ from 150 sorted HSCs from *Mx-1cre; Mettl3*^*fl/fl*^ or control mice 10 days after pIpC treatment. Three control and four *Mx-1cre; Mettl3*^*fl/fl*^ biological replicate samples were sequenced by Illumina HiSeq 2500 with paired-end 100-bp read length.

For meRIP-seq, poly(A)+RNA was isolated from 3,000 sorted HSCs from C57BL/6J mice or *Mx-1cre; Mettl3*^*fl/fl*^ mice 10 days after pIpC injection using Dynabeads Oligo-(dT)25 magnetic beads (ThermoFisher Scientific) according to manufacturer's instructions. 1.25 μg of anti-m^6^A antibody (Synaptic Systems) or rabbit IgG (Jackson ImmunoResearch) was pre-bound to Protein A/G magnetic beads (Millipore) in IP buffer (20-mM Tris pH 7.5, 140-mM NaCl, 1% NP-40, 2-mM EDTA) for 1 h. Sample RNA was incubated with antibody-bound Protein A/G beads for 2 hours at 4 °C. Samples were washed twice in low-salt-wash buffer (10-mM Tris pH 7.5, 5 mM EDTA), twice with high-salt-wash buffer (20-mM Tris pH 7.5, 1-M NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1-mM EDTA) and twice with RIPA buffer (20-mM Tris pH 7.5, 150-mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1-mM EDTA). All wash solutions for each sample were collected as the "unbound" fraction. RNA was eluted from the beads by incubating with 50μl 20mM N6-methyladenosine 5-monophosphate sodium salt (Sigma) for 1hr at 4 °C. Following ethanol precipitation, RNA from input, m^6^A-antibody unbound, and m^6^A-antibody eluted, and IgG eluted fractions was reverse transcribed, amplified, tagmented and index according to the Smart-seq2 protocol^[@R27]^. Three biological replicate samples were sequenced by Illumina HiSeq 2500 or NextSeq 500 with paired-end 100-bp or 150-bp read length.

Analysis of RNA-seq and meRIP-seq data was performed using the Quantas pipeline (<https://zhanglab.c2b2.columbia.edu/index.php/Quantas>)^[@R42]^ with minor modifications. In brief, raw reads were mapped to the mouse genome and an exon-junction database using OLego^[@R43]^. Due to the low input during library preparation, potential PCR duplicates were removed using Picard (<http://broadinstitute.github.io/picard>). Exonic and junction reads were then counted to estimate transcript abundance (read per kilobase per million reads, or RPKM) and perform differential expression analysis using edgeR^[@R44]^.

Cumulative distribution analysis of RNA-seq log~2~ fold changes in expression between *Mettl3*-depleted and control HSCs was performed in R using the ecdf function. Groups were defined as m^6^A (meRIP-seq FDR\<0.05, FC\>2) or non-m^6^A (the rest of the genes), excluding genes with RNA-seq RPKM \<1 for both *Mettl3*-depleted and control HSCs. Significance of difference between the cumulative distribution curves was determined using Kolmogorov--Smirnov test.

Statistics and Reproducibility {#S25}
------------------------------

All experiments were repeated on biological replicates independently with similar results. The exact sample sizes for each experiment were indicated in figure legends. All statistics comparing two groups used two-sided Student t-test. The Kaplan-Meier estimation and two-sided log-rank test were used to compare survival difference between mouse groups. Statistical analyses were performed with Microsoft Excel or GraphPad Prism7. Statistical source data were included in [Supplementary Table 3](#SD5){ref-type="supplementary-material"}.

Reporting Summary {#S26}
-----------------

Further information regarding research design is available in the Nature Research Reporting Summary associated with this article.

Data Availability {#S27}
-----------------

Sequencing data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE123527. Source data have been provided as [Supplementary Table 3](#SD5){ref-type="supplementary-material"}. All other data supporting the findings of this study are available from the corresponding authors on reasonable request.
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![Loss of *Mettl3* leads to accumulation of HSCs and perturbed haematopoiesis.\
(**a**,**b**) White blood cell (WBC) (**a**) and platelet peripheral blood counts (**b**) from pIpC-treated control and *Mx1-cre; Mettl3*^*fl/fl*^ mice (n=7 control (10--14d), n=7 *Mx1-cre; Mettl3*^*fl/fl*^ (10--14d), n=4 control (2--3m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (2--3m), n=3 control (4m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (4m)).\
(**c**) Bone marrow cellularity per hindlimb (n=28 control (10--14d), n=8 *Mx1-cre; Mettl3*^*fl/fl*^ (10--14d), n=5 control (2--3m), n=6 *Mx1-cre; Mettl3*^*fl/fl*^ (2--3m), n=4 control (4m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (4m)).\
(**d**) Representative images of the spleens from *Mx1-cre; Mettl3*^*fl/fl*^ and control mice 10 days and 3 months after pIpC treatment, as indicated.\
(**e**) Spleen cellularity (n=8 control (10--14d), n=8 *Mx1-cre; Mettl3*^*fl/fl*^ (10--14d), n=5 control (2--3m), n=6 *Mx1-cre; Mettl3*^*fl/fl*^ (2--3m), n=4 control (4m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (4m)).\
(**f**) Spleen HSC frequency (n=6 control (10--14d), n=5 *Mx1-cre; Mettl3*^*fl/fl*^ (10--14d), n=6 control (2--3m), n=6 *Mx1-cre; Mettl3*^*fl/fl*^ (2--3m), n=4 control (4m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (4m)).\
(**g**) Frequencies of bone marrow Lin^−^Sca-1^+^c-Kit^+^ (LSK) progenitors (n=7 control (10--14d), n=6 *Mx1-cre; Mettl3*^*fl/fl*^ (10--14d), n=6 control (2--3m), n=7 *Mx1-cre; Mettl3*^*fl/fl*^ (2--3m), n=4 control (4m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (4m)).\
(**h**) Frequency of bone marrow HSCs (n=7 control (10--14d), n=6 *Mx1-cre; Mettl3*^*fl/fl*^ (10--14d), n=6 control (2--3m), n=7 *Mx1-cre; Mettl3*^*fl/fl*^ (2--3m), n=4 control (4m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (4m)).\
(**i**) Fold increase in *Mx1-cre; Mettl3*^*fl/fl*^ bone marrow HSC or MPP frequency compared to littermate control frequencies at indicated times after pIpC treatment (n=6 (10--14d), n=7 (2--3m), n=4 (4m)).\
(**j**) Frequencies of mature cell populations in the bone marrow (n=4 control (10--14d), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (10--14d), n=5 control (2--3m), n=5 *Mx1-cre; Mettl3*^*fl/fl*^ (2--3m), n=4 control (4m), n=4 *Mx1-cre; Mettl3*^*fl/fl*^ (4m)).\
(**k**) Frequency of megakaryocyte progenitors (Lineage^−^Sca1^−^cKit^+^CD150^+^CD41^+^) cells in the bone marrow \>10 days after pIpC treatment (n=5 control, n=6 *Mx1-cre; Mettl3*^*fl/fl*^).\
All samples are from biologically independent mice. Values are shown as individual points with mean ± s.d. P values were determined by unpaired two-sided Student's t-test.](nihms-1525419-f0001){#F1}

![*Mettl3* is essential for adult HSC differentiation *in vitro*.\
(**a**) Frequency of BrdU^+^ HSCs 10--14 days after pIpC treatment (n=4 for control, n=4 for *Mx1-cre; Mettl3*^*fl/fl*^).\
(**b**) Frequency of DAPI^−^ AnnexinV^+^ HSC, MPP and LSK populations 10--14 days after pIpC (n=6 for control, n=6 for *Mx1-cre; Mettl3*^*fl/fl*^).\
(**c**) Kaplan-Meyer survival analysis of control and *Mx1-cre; Mettl3*^*fl/fl*^ mice treated with weekly 5-FU injections 10 days after the last dose of pIpC. P value by log-rank test (n=4 for control, n=4 for *Mx1-cre; Mettl3*^*fl/fl*^).\
(**d**) Frequencies of colony formation from single sorted HSCs. Colony-forming units (CFU) scored as granulocyte, erythroid, macrophage, megakaryocyte (GEMM), granulocyte, macrophage (GM), megakaryocyte (Mk), or erythrocyte (E) colonies (n=7 for control, n=7 for *Mx1-cre; Mettl3*^*fl/fl*^).\
(**e**) Representative image of CFU-GM from single HSCs from control (left) and *Mettl3*-deleted (right) single HSCs, genotypes confirmed by PCR. Scale bars are 400um.\
(**f**) Representative flow cytometric histograms of mature myeloid cell surface markers Gr-1 and Mac-1 on HSC-derived colony cells from pIpC-treated control and *Mx1-cre; Mettl3*^*fl/fl*^ mice.\
(**g**) Numbers of colonies formed from 10,000 bone marrow cells, scored as CFU-GEMM, CFU-GM, CFU-E, or CFU-MK (n=5 for control, n=5 for *Mx1-cre; Mettl3*^*fl/fl*^).\
(**h**) Quantification of expression of Gr-1 and Mac-1 cell surface markers on HSC and LSK colony cells by flow cytometry (HSC, n=8 for control, n=6 for *Mx1-cre; Mettl3*^*fl/fl*^; LSK, n=6 for control, n=6 for *Mx1-cre; Mettl3*^*fl/fl*^).\
All samples are from biologically independent animals. Values are shown as individual points with mean ± s.d. P values were determined by unpaired two-sided Student's t-test.](nihms-1525419-f0002){#F2}

![Loss of *Mettl3* disrupts HSC differentiation *in vivo*.\
(**a**) Competitive transplantation of 500,000 donor whole bone marrow cells from pIpC-treated *Mx1-cre; Mettl3*^*fl/fl*^ or *Mettl3*^*fl/fl*^ controls with 500,000 competitor cells. Multi-lineage chimera levels in the peripheral blood were assessed up to 16 weeks after transplantation (n=7 for control, n=8 for *Mx1-cre; Mettl3*^*fl/fl*^; samples were from independent recipients of two independent donor pairs from two experiments).\
(**b**) Competitive transplantation of 50 sorted HSCs from pIpC-treated *Mx1-cre; Mettl3*^*fl/fl*^ or controls with 300,000 competitor cells. Multi-lineage chimera levels in the peripheral blood were assessed up to 16 weeks after transplantation (n=9 for control, n=9 for *Mx1-cre; Mettl3*^*fl/fl*^; samples were from independent recipients of two independent donor pairs from two experiments).\
(**c**) 500,000 donor whole bone marrow cells from untreated *Mx1-cre; Mettl3*^*fl/fl*^ or controls with 500,000 competitor cells were transplanted into lethally irradiated recipient mice. Recipients were treated with pIpC after stable peripheral blood chimerism was established. Multi-lineage peripheral blood chimera levels shown as the percentage of the original chimera level up to 16 weeks after pIpC treatment (n=11 for control, n=12 for *Mx1-cre; Mettl3*^*fl/fl*^; samples were from independent recipients of three independent donor pairs from three experiments).\
(**d**) Chimera levels of indicated bone marrow cell populations 20 weeks after pIpC treatment from (**c**) (n=9 for control, n=9 for *Mx1-cre; Mettl3*^*fl/fl*^; samples were from independent recipients of three independent donor pairs from three experiments).\
Values are shown as individual points with mean ± s.d. P values were determined by unpaired two-sided Student's t-test.](nihms-1525419-f0003){#F3}

![Loss of *Mettl3* has no impact on myeloid cell maintenance or function.\
(**a**) White blood cell counts in *LysM-cre; Mettl3*^*fl/fl*^ mice (n=6 for control, n=6 for *LysM-cre; Mettl3*^*fl/fl*^).\
(**b**) Frequencies of differential white blood cell counts in *LysM-cre; Mettl3*^*fl/fl*^ mice (n=6 for control, n=6 for *LysM-cre; Mettl3*^*fl/fl*^).\
(**c**) Bone marrow cellularity (n=5 for control, n=5 for *LysM-cre; Mettl3*^*fl/fl*^).\
(**d**) Frequencies of bone marrow (left) and spleen (right) neutrophils (Mac1^+^Gr1^+^) and macrophages (Mac1^+^F4/80^+^) by flow cytometry (n=5 for control, n=5 for *LysM-cre; Mettl3*^*fl/fl*^).\
(**e**) qPCR analysis of cytokine expression by unstimulated and LPS-stimulated bone marrow macrophages (n=3 for control, n=3 for *LysM-cre; Mettl3*^*fl/fl*^).\
(**f**) Representative histogram (left) and quantification (right) of bone marrow macrophage phagocytosis of fluorescent-labeled beads (n=3 for control, n=3 for *LysM-cre; Mettl3*^*fl/fl*^). Shaded area denotes background staining (4°C incubation).\
All samples were from biologically independent animals. Values are shown as individual points with mean ± s.d. P values were determined by unpaired two-sided Student's t-test.](nihms-1525419-f0004){#F4}

![Identification of m^6^A methylation targets in HSCs.\
(**a**) Heat map of transcript abundance between input, m^6^A-tagged, and unbound fractions. A total of 5,676 genes with log2(RPKM) ≥5 in ≥4 samples and stdev\[log2(RPKM)\]≥0.6 are shown.\
(**b**) Volcano plot of meRIP-seq transcript expression differences between m^6^A-tagged and unbound fractions in HSCs. The x-axis specifies the log2 fold-changes (FC) and the y-axis specifies the log2 false discovery rate (FDR). Dashed vertical and horizontal lines indicate the filtering criteria (log2(FC)\>1 and FDR\<0.05). Orange dots represent 2,621 transcripts showing statistically significant differences between bound and non-bound factions, of which 2,073 are significantly enriched in the m^6^A-tagged fraction.\
(**c**) meRIP-seq data showing that transcripts of some known HSC regulators are m^6^A-tagged in wild-type HSCs, and this methylation is largely eliminated in *Mx1-cre; Mettl3*^*fl/fl*^ (*Mettl3*^*Δ/Δ*^) HSCs 10 days after Cre induction. Data were from n=3 biologically independent samples for control and *Mettl3*^*Δ/Δ*^. Values are shown as individual points with mean ± s.d.\
(**d**) Gene set enrichment analysis plots showing that *Mettl3*-deficient HSCs lose HSC gene signature, as determined by RNA-seq profiling. Analysis completed on gene list ranked by log~10~ FDR and fold change sign, with enrichment determined after 1,000 permutations. Data were from n=3 biologically independent samples for control and *Mettl3*^*Δ/Δ*^. The statistics was computed using GSEA, and controlled for multiple comparisons by false discovery rate.\
(**e**) Cumulative distribution of log~2~ (gene expression ratios, *Mettl3*-deficient/control). Genes were separated as m^6^A and non-m^6^A as assessed by meRIP-seq. Insert is the box plot of the log~2~ fold change in expression of non-m^6^A and m^6^A targets in HSCs. Plot displays the mean, standard deviation and interquartile range. P value was determined by two-sided Kolmogorov-Smirnov test.\
All sequencing data were from n=3 biologically independent animals for control and *Mettl3*^*Δ/Δ*^.](nihms-1525419-f0005){#F5}

![*Mettl3* regulates HSC function by targeting *Myc*.\
(**a**) meRIP-qPCR data showing *Myc* enrichment in m^6^A-bound fraction in control and *Mx1-cre; Mettl3*^*fl/fl*^ HSCs 10 days after pIpC treatment (n=3 for control, n=4 for *Mx1-cre; Mettl3*^*fl/fl*^). Data shown were normalized to the expression of *Rplp0*, a target found not to be methylated in HSCs by our meRIP-Seq analysis.\
(**b**) Gene set enrichment analysis plots, as determined by HSC RNA-seq profiling of control and *Mx1-cre; Mettl3*^*fl/fl*^ HSCs 10 days after pIpC treatment (n=3 for control and *Mettl3*^*Δ/Δ*^). *Mettl3*-deficient HSCs significantly lose *Myc* target genes. Analyses were completed on gene list ranked by log~10~ FDR and fold-change sign. P values were determined by the GSEA algorithm after 1,000 permutations. The statistics was computed using GSEA, and controlled for multiple comparisons by false discovery rate.\
(**c**) Quantification of the mean fluorescence intensity (MFI) of GFP expression in LSK subsets from *Mx1-cre; Mettl3*^*fl/fl*^*; Myc-GFP* mice or *Myc-GFP* controls at least 10 days after pIpC treatment (n=4 for *Myc-GFP* controls, n=4 for *Mx1-cre; Mettl3*^*fl/fl*^*; Myc-GFP)*. Values were normalized to GFP-negative control cells of the same population.\
(**d**) Schematic of experimental design (top). Representative FACS plots of MYC-GFP expression in HSCs at steady-state (left) and after cytokine activation (right). Quantification of the mean fluorescence intensity (MFI) of GFP expression in HSCs after cytokine activation (n=7 for *MYC-GFP* controls, n=7 for *Mx1-cre; Mettl3*^*fl/fl*^*; MYC-GFP)*. Values were normalized to GFP-negative control cells.\
(**e**) Schematic of experimental design (left). Representative FACS plot (middle) and quantification (right) of the frequency of Mac-1^+^ cells in virally transduced colonies from sorted HSCs from *Mx1-cre; Mettl3*^*fl/fl*^ mice 10 days after pIpC treatment (n=3 for pMIG, n=3 for pMIG-*Myc*).\
All samples were from biologically independent animals. Values are shown as individual points with mean ± s.d. P values were determined by paired two-sided Student's t-test.](nihms-1525419-f0006){#F6}
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